PE20141452A1 - Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan - Google Patents

Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan

Info

Publication number
PE20141452A1
PE20141452A1 PE2013002500A PE2013002500A PE20141452A1 PE 20141452 A1 PE20141452 A1 PE 20141452A1 PE 2013002500 A PE2013002500 A PE 2013002500A PE 2013002500 A PE2013002500 A PE 2013002500A PE 20141452 A1 PE20141452 A1 PE 20141452A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
salmonella gallinarum
salmonella
strains
modified salmonella
Prior art date
Application number
PE2013002500A
Other languages
English (en)
Inventor
Hyang Choi
Soo An Shin
Si Yong Yang
Young Wook Cho
Original Assignee
Cj Cheiljedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corp filed Critical Cj Cheiljedang Corp
Publication of PE20141452A1 publication Critical patent/PE20141452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A CEPAS DE SALMONELLA GALLINARUM MODIFICADAS, EN LA QUE SE REDUCE LA PATOGENIA POR INACTIVACION DE UNA AGRUPACION DE GENES SELECCIONADA DEL GRUPO QUE CONSISTE EN LA ISLA DE PATOGENIA DE SALMONELLA 1, LA ISLA DE PATOGENIA DE SALMONELLA 2, SPVRABCD Y FAEHI, DICHAS CEPAS TIENEN EL NUMERO DE ACCESO DE KCCM11009P. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA LA PREVENCION Y TRATAMIENTO DE LA TIFOSIS AVIAR.
PE2013002500A 2011-05-17 2012-05-17 Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan PE20141452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487137P 2011-05-17 2011-05-17
US13/274,854 US8481052B2 (en) 2011-05-17 2011-10-17 Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same

Publications (1)

Publication Number Publication Date
PE20141452A1 true PE20141452A1 (es) 2014-10-23

Family

ID=47175080

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002500A PE20141452A1 (es) 2011-05-17 2012-05-17 Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan

Country Status (10)

Country Link
US (3) US8481052B2 (es)
EP (1) EP2710116B1 (es)
KR (1) KR101500805B1 (es)
CN (2) CN104053768B (es)
BR (1) BR112013029677A2 (es)
CL (2) CL2013003285A1 (es)
DO (1) DOP2013000270A (es)
ES (1) ES2724729T3 (es)
PE (1) PE20141452A1 (es)
WO (1) WO2012157989A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
KR101465605B1 (ko) * 2013-01-25 2014-11-27 강원대학교산학협력단 ssrAB, rpoS 및 hmp 유전자가 결손된 살모넬라 갈리나룸 균주 및 이를 유효성분으로 포함하는 가금 티프스 예방용 백신 조성물
WO2016077453A1 (en) * 2014-11-11 2016-05-19 Ohio State Innovation Foundation Probiotic bacteria for the prevention and treatment of salmonella
KR101774863B1 (ko) 2015-07-20 2017-09-05 강원대학교산학협력단 살모넬라증 치료를 위한 변이 균주 ｈｉｄ２０９２와 ｈｉｄ２１１４ 및 이를 포함하는 살모넬라증 약제학적 조성물
BR112018010737A2 (pt) 2015-11-25 2018-11-27 Universidad De Los Andes composição compreendendo bacteriófagos para reduzir, eliminar e/ou prevenir a salmonella enteritidis, salmonella typhimurium e salmonella paratyphi b
CN109486714B (zh) * 2018-12-07 2020-08-04 扬州大学 一种鸡伤寒沙门氏菌弱毒分离株及其应用
US20200305461A1 (en) * 2019-03-29 2020-10-01 Purina Animal Nutrition Llc Bacteriophage animal feed preservative
KR102327091B1 (ko) * 2020-06-18 2021-11-16 전남대학교 산학협력단 암의 치료용 살모넬라 균주 및 이의 용도
CN117480255A (zh) * 2021-04-30 2024-01-30 全南大学校产学协力团 减毒鸡沙门氏菌菌株及其用途
KR20220159914A (ko) * 2021-05-26 2022-12-05 서울대학교산학협력단 살모넬라 갈리나룸 변이균주 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ296581A (en) * 1994-12-09 2000-02-28 Imp College Innovations Ltd A method of identifying genes identified in a microorganisms ability to adapt to changes in its environment
AU5860599A (en) * 1998-09-04 2000-03-27 Creatogen Aktiengesellschaft Attenuated salmonella spi2 mutants as antigen carriers
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
MXPA02008748A (es) 2000-03-17 2003-02-24 Upjohn Co Materiales y metodos para vacuna antisalmonella.
KR100436740B1 (ko) * 2003-09-20 2004-06-22 주식회사 인트론바이오테크놀로지 살모넬라 갈리나룸 약독주 및 이를 포함하는 가금티푸스예방용 백신 조성물
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101204584A (zh) * 2007-12-17 2008-06-25 北京娜可长今国际银离子科技开发有限公司 以减毒沙门氏菌为载体的肿瘤疫苗及其制备方法
KR101070938B1 (ko) * 2008-12-02 2011-10-06 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101151532B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101151516B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
US8647640B2 (en) * 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same

Also Published As

Publication number Publication date
US9192658B2 (en) 2015-11-24
WO2012157989A2 (en) 2012-11-22
US8524243B2 (en) 2013-09-03
US20130202643A1 (en) 2013-08-08
CL2017000232A1 (es) 2017-07-28
US20130022574A1 (en) 2013-01-24
CN107083351B (zh) 2021-09-14
CN104053768A (zh) 2014-09-17
CL2013003285A1 (es) 2014-06-13
KR20120128583A (ko) 2012-11-27
EP2710116B1 (en) 2019-03-27
DOP2013000270A (es) 2014-03-31
EP2710116A4 (en) 2014-12-24
EP2710116A2 (en) 2014-03-26
KR101500805B1 (ko) 2015-03-09
BR112013029677A2 (pt) 2017-01-24
CN107083351A (zh) 2017-08-22
ES2724729T3 (es) 2019-09-13
WO2012157989A3 (en) 2013-01-24
CN104053768B (zh) 2020-10-30
US8481052B2 (en) 2013-07-09
US20120294892A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
CY1124486T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
AR102657A1 (es) Composición para tratar telas
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
UY33665A (es) Derivado peptídico
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
DOP2016000253A (es) Nuevos compuestos
PE20181133A1 (es) Bacteria lactobacillus fermentum con actividad antifungica
AR102658A1 (es) Composición para el tratamiento de telas
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
PH12017500637A1 (en) Inhibitors of lysine gingipain
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
CO2018010937A2 (es) Sistemas de formulación para glicolípidos antimicrobianos
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112017007863A2 (pt) composição para o tratamento de condições envolvendo dor muscular
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático

Legal Events

Date Code Title Description
FG Grant, registration